Broadcast on November 10, 2016

This webinar is now available on-demand
If you have already registered for this event, please login
using the link provided in your registration confirmation email

Therapeutic proteins and peptides have emerged as one of the most important classes of new pharmaceuticals. Several drug candidates with potential performance-enhancing properties are currently in preclinical or clinical development. The current version of the WADA Prohibited List includes a variety of protein/peptide-based doping agents, some of which can be detected in biological samples by using immunological and mass spectrometry-based approaches.

Dr. Katja Walpurgis and Andreas Thomas of the Center for Preventive Doping Research of the German Sport University Cologne will present novel classes of protein-/peptide-based drugs such as Fc-fusion proteins and discuss strategies for their detection in doping control samples by means of the ACQUITY UPLC System and the SYNAPT G2S.

What will I learn?

How novel protein-/peptide-based drugs such as Fc-fusion proteins and therapeutic antibodies can be detected in human matrices by using different proteomics techniques in combination with high resolution mass spectrometry.

How ion mobility can help to identify prohibited substances in complex biological matrices.